Xenon Pharmaceuticals (XENE) is the lead sponsor of 9 active clinical trials listed on ClinicalTrials.gov[3], including 8 Phase 3[1], 1 Phase 2[2].
Trial NCT05716100[4] evaluates XEN1101 in Focal Onset Seizures with a target enrollment of 360 participants. Trial NCT07172516[5] evaluates Azetukalner in Bipolar Disorder with a target enrollment of 400 participants. Trial NCT06775379[6] evaluates Azetukalner in Major Depressive Disorder with a target enrollment of 450 participants.
XENE has 3 Form 4 insider filings recorded at the SEC in the past 30 days[7].